Effect of tablet Melatonin on prevention of Confusion in severe COVID 19 patients admitted in IC
Phase 4
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: U071- COVID 19 virus identified
- Registration Number
- CTRI/2021/12/038630
- Lead Sponsor
- Dr Suhasini Hubli
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
RTPCR / CT proven COVID-19 pneumonia with saturation less than 93%.
Exclusion Criteria
Post cardiac arrest
Patients on opioid antagonist, chronic opioid or sleeping pills, SSRI, Monoamine oxidase inhibitors, central nervous system depressants
Patients with cerebrovascular accident and other CNS disorders.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the effect of melatonin on incidence of onset of delirium on day 3 of delirium <br/ ><br>Timepoint: Day 3rd of icu <br/ ><br>
- Secondary Outcome Measures
Name Time Method To study the effect of melatonin on mortality, icu stay, duration of ventilator supportTimepoint: Number of day in icu and on duration of ventilator support in days